ProPhase Labs announced its 2025 financial results, highlighting $201.2 million in gross claims under its Crown Medical Collections platform, with $79.9 million in active insurance settlement negotiations. The company estimates a net recovery of $50 to $60 million, potentially generating meaningful cash flow starting Q3 2026, which could improve liquidity. ProPhase is also advancing its Nebula Genomics platform and BE-Smart esophageal cancer diagnostic toward commercialization, aiming for growth and strategic partnerships. Despite a net loss of $13.4 million in 2025, the company is focusing on stabilizing liquidity and expanding its receivables platform's financeability.
Leading Japanese companies, startups, and research institutions are developing specialized AI models using NVIDIA Nemotron open models to address Japan's unique language, industrial, and workforce challenges. These AI applications range from enterpri...
ARCpoint Inc. announced it will likely miss the July 29, 2026 deadline to file its annual financial statements and related reports due to a lack of funds to pay auditors. The company has applied for a Management Cease Trade Order (MCTO) and awaits ap...
The Rosen Law Firm is investigating potential securities claims against Putnam Investment Management, LLC, alleging that the company may have provided misleading business information to investors. Investors who purchased Putnam stock-based mutual fun...
Ondo Global Markets reached $1 billion in total value locked (TVL) for tokenized stocks by May 2026, with projections to hit $5 billion by year-end. USDC, Circle's stablecoin, is the preferred settlement currency for these tokenized equities, favored...
Ademi LLP is investigating GPGI for potential securities fraud related to alleged inaccurate statements about its financials and business operations, especially concerning its acquisition of Husky Technologies Limited. This probe could impact investo...
